Brepocitinib Overview & RVT-3101 Update

RVT-3101 Shows Consistent Effect Across Endpoints and Patient Populations Results were statistically significant for pooled drug and at each individual dose tested Clinical Remission (Modified Mayo) RVT-3101 Placebo Endoscopic Improvement ■RVT-3101 Placebo 45% 65% 40% Pbo-adj A = 27% p = 0.02 60% Pbo-adj A = 41% 55% Pbo-adj A = 21% p = 0.002 35% p = 0.01 37% 50% 45% Pbo-adj A = 21% 51% 30% 32% p = 0.01 40% 25% 35% 40% 30% 20% 25% 15% 20% 10% 12% 15% 19% 10% 10% 5% 10% 5% 0% 0% All-Comers Pooled Biomarker Positive Pooled All-Comers Pooled Biomarker Positive Pooled • roivant In -20% of patients across the study, biomarker was not analyzed due to lack of consent at specific sites • Among patients for whom biomarker status was analyzed, biomarker positive or negative status was determined in 100% of patients One-sided p-value of difference of proportions were computed using Chan And Zhang (1999) method, in accordance with Pfizer prespecified statistical analysis plan. Statistical significance considered to be a p-value ≤ 0.025. Values that are not significant are marked "NS" Placebo-adjusted delta values may not exactly match the difference between gross and placebo values due to rounding. For investor audiences only 9

View entire presentation